A Phase 3 interventional study of Valsartan 160 mg capsules and Amlodipine 5 mg capsules in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 12 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2014-11-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing valsartan in Essential Hypertension — 2 open to participants now, 2 under way, 1 of them phase 3. Valsartan · Essential Hypertension.
Among the 10 studies testing valsartan in Essential Hypertension, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 4 in phase 3, and was the 3rd registered.
480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →2 of the 10 studies testing valsartan in Essential Hypertension are open now, in 1 country. Recruiting first, the newest first:
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 6–17
Sichuan Academy of Medical Sciences · Sites in China
Ages 18+
By country, each count listing its studies:
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,183 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.
Median enrollment 392 across the 10 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Essential Hypertension by Novartis: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2007, is one of 15 in phase 3, and was the 5th registered.
Novartis’s Essential Hypertension studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing valsartan in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean sitting systolic blood pressure [msSBP] ≥ 130 mmHg and ≤ 160 mmHg) on amlodipine 5 mg alone. The study evaluated both the efficacy and tolerability of the treatments by providing data that assessed blood pressure and the proportion of patients developing peripheral edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
Drug: Valsartan 160 mg capsules · Drug: Amlodipine 5 mg capsules · Drug: placebo
Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
Drug: Valsartan 160 mg capsules · Drug: Amlodipine 5 mg capsules · Drug: placebo
capsules
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
Time frame: Baseline to Week 8
Percentage of Patients With Peripheral Edema From Baseline to Week 8
Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis.
Time frame: Baseline to Week 8
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
Time frame: Baseline to Week 8
Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
Time frame: Baseline to Weeks 4, 8, and 12
Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12
Systolic response was defined as msSBP \< 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.
Time frame: Baseline to Weeks 4, 8, and 12
| Milestone | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Started | 592 | 591 |
| Completed | 557 | 476 |
| Not completed | 35 | 115 |
| Withdrew: Adverse event | 15 | 84 |
| Withdrew: Withdrawal by subject | 10 | 22 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Administrative problems | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Condition no longer requires study drug | 1 | 1 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
| mmHg | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8 | -8.01 ± 0.5944 | -6.30 ± 0.6088 |
Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis.
| Percentage of patients | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Percentage of Patients With Peripheral Edema From Baseline to Week 8 | 6.6 | 31.1 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
| mmHg | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8 | -4.65 ± 0.3616 | -4.13 ± 0.3690 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.
| mmHg | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| msSBP: Week 4 (n=576, 535) | -8.40 ± 0.5559 | -6.48 ± 0.5676 |
| msSBP: Week 8 (n=567, 510) | -8.15 ± 0.6065 | -6.11 ± 0.6266 |
| msSBP: Week 12 (n=569, 531) | -9.08 ± 0.6968 | -7.82 ± 0.7088 |
| msDBP: Week 4 (n=576, 535) | -5.05 ± 0.3559 | -4.23 ± 0.3623 |
| msDBP: Week 8 (n=576, 510) | -4.68 ± 0.3632 | -3.97 ± 0.3736 |
| msDBP: Week 12 (n=569, 531) | -5.50 ± 0.03735 | -4.90 ± 0.3785 |
Systolic response was defined as msSBP \< 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.
| Percentage of patients | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Week 4 (n=576, 535) | 35.07 | 25.42 |
| Week 8 (n=567, 510) | 34.22 | 25.49 |
| Week 12 (n=569, 531) | 37.96 | 31.26 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan/Amlodipine 160/5 mg | — | 11/592 (1.9%) | 61/592 (10.3%) |
| Amlodipine 10 mg | — | 8/591 (1.4%) | 201/591 (34%) |
| Event | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| CholecystitisHepatobiliary disorders | 2/592 | 0/591 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/592 | 1/591 |
| Gastrointestinal necrosisGastrointestinal disorders | 0/592 | 1/591 |
| Inguinal herniaGastrointestinal disorders | 0/592 | 1/591 |
| Humerus fractureInjury, poisoning and procedural complications | 0/592 | 1/591 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/592 | 1/591 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/592 | 1/591 |
| Cerebrovascular accidentNervous system disorders | 0/592 | 1/591 |
| DysphasiaNervous system disorders | 0/592 | 1/591 |
| Neglect of personal appearancePsychiatric disorders | 0/592 | 1/591 |
| Event | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg |
|---|---|---|
| Oedema peripheralGeneral disorders | 43/592 | 186/591 |
| HeadacheNervous system disorders | 18/592 | 33/591 |
| Age, Continuous(Age (years)) | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Overall study | 65.6 ± 7.56 | 65.4 ± 7.16 | 65.5 ± 7.36 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine 160/5 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Female | 285 | 284 | 569 |
| Male | 307 | 307 | 614 |
The record gives a start of Jan 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine